Luoda is developing a unique oral liquid combination product to improve compliance and effectiveness.
Congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation) in dogs.
| Development Status: | Clinical Development Ongoing |
| Licence Status: | First stage funding obtained |
| Commercialisation Date: | Estimated 2019 |
Luoda has invented, patented, developed, registered and manufactured a novel oral liquid formulation of pimobendan to improve ease and reliability of administration, compliance and effectiveness.
Congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation) in dogs.
| Development Status: | Registration submitted |
| Licence Status: | Partner / funding secured |
| Commercialisation Date: | November 2016 |
